Many people with rheumatoid arthritis (RA) has been told they have a higher risk cancer because of disease and treatment, such as biological and immunosuppressants, undergoing.
But what these patients, and perhaps even their doctors did not know until recently is that cancer drugs can cause AR, too.
There has been a long-known link between cancer and rheumatoid arthritis. Generally, the risk has been reported that RA patients face a high risk of cancer, but not vice versa.
A recent study published in the Annals of Rheumatic Disease recommends that oncologists should now monitor patients with cancer who undergo immunotherapy treatments because these therapies may put patients at increased risk of developing RA .
Read more: Stem cell treatment a possible therapy for rheumatoid arthritis “
Many patients with RA and others with chronic autoimmune diseases have a hematologist or a medical oncologist in their “toolbox.”
However, a rheumatologist is not necessarily a physician that a cancer patient would be working with.
oncologists should be aware of this new potential for patients with rheumatic diseasesamong cancer who have been treated with a class of drugs called angiotensin immunological control point (ICI), according to the study authors.
The team of 13 researchers followed 13 patients who received the ICI and developed adverse events related to the immune system (REST index).
The average age of study participants was 58 years, and their cancers including skin cancer, lung cancer and renal cell carcinoma.
Nine of these patients developed inflammatory arthritis was diagnosed through imaging or testing of the synovial joint fluid.
Four patients developed Sjogren’s syndrome, which is also a rheumatic disease.
All cancer patients had rheumatic autoimmune conditions and others were only at ICI for a short time, and developed their IRAE in nine months or less after treatment.
Read more: Rheumatoid arthritis associated with disorders of severe mood “
A new surveillance
The researchers said the turnaround short highlights took place quickly immunological and rheumatological manifestations.
Patients who developed symptoms were put on corticosteroids, a common treatment for RA. Some also received methotrexate or a biological agent such as a drug of tumor necrosis factor (anti-TNF), which are also common therapies for RA.
In the full version of the published report, the study authors concluded that, “Recognizing the potential of ICI to cause REST index that resemble the classic autoimmune diseases will be increasingly important for rheumatologists as more patients are referred for evaluation and management, and for that oncologists should recognize these toxicities order of reference. “
the team also noted the” need for careful assessment baseline and after [up] of these patients by rheumatologists. ” The researchers also stated in a press release regarding the published study, coordinated and cooperative effort among rheumatologists is not only crucial, but it can become the new normal, saying that such a relationship “will be essential to understand the spectrum REST index rheumatological and treatment. ”
Oncologists have to be vigilant in investigating symptoms reported by patients and the results of blood tests in order to decide when to refer to a cancer patient to a rheumatologist.